Jacinda Abdul-Mutakabbir, PharmD
Articles by Jacinda Abdul-Mutakabbir, PharmD

Health Care Is a Human Right: A Roundtable on Values, Visibility, and the Work Ahead
ByJacinda Abdul-Mutakabbir, PharmD,Omolola (Lola) Adeoye-Olatunde, PharmD, MS,Tyler Marie Kiles, PharmD, MPH, BC-ADM,Alana Hippensteele, Lead Editor In this roundtable, 3 pharmacy faculty members reflect on how shifting federal priorities and the defunding of research initiatives have impacted their work, communities, and careers—while highlighting the power of resilience, solidarity, and reimagined academic impact in advancing public health equity.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.

CDC and FDA Recommendations for SARS-CoV-2 Booster Shots
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Experts in the management of SARS-CoV-2 educate on CDC and FDA recommendations for approaching administration of booster vaccines, including those for special patient populations.

Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients.

Evolution of SARS-CoV-2 Variants on Booster Shot Development and Formulations
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc, leads a discussion on the constant evolution of SARS-CoV-2 variants and the impact on vaccine and booster shot development and administration.

COVID-19 Booster Vaccination Protection Rates
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Jacinda Abdul-Mutakabbir, PharmD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; and Madeline King, PharmD, BCIDP, examine the efficacy and real-world implications of the COVID-19 booster shot in terms of vaccination protection rates.

Impact of SARS-CoV-2 Subvariants on Vaccination
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, leads a discussion on the challenges subvariants of SARS-CoV-2 present in terms of vaccination and approaching optimal communication to the public surrounding vaccination.

Defining Variants of Interest vs Variants of Concern
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Expert health professionals share their thoughts on variants of concern vs variants of interest of the SARS-CoV-2 strains as they relate to clinical practice.

Overview of SARS-CoV-2 Virus and Subvariants
ByRodney Rohde, SV, SM, MB (ASCP), FACSc,Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP,Jacinda Abdul-Mutakabbir, PharmD,Madeline King, PharmD, BCIDP Jacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.